Securities America reps finally see closure in class action settlement

Securities America reps finally see closure in class action settlement
Judge approves settlement; brokers with arbitration claims now can put matter behind them
JUN 16, 2011
A federal judge's approval last week of a class action settlement is good news for representatives from Securities America Inc. whose disgruntled clients named them in arbitration complaints over sales of private placements that have gone bust. Last Thursday, U.S. District Court Judge W. Royal Furgeson Jr. in Dallas signed an order to approve an $80 million settlement between Securities America and class action investors suing the firm over two series of private placements, Medical Capital Holdings Inc. and Provident Royalties LLC. In April, a separate $70 million settlement was reached with investors who had filed individual arbitration claims against some brokers. With the settlement approved, reps and financial advisers at Securities America whose employment records were tarred with open or pending arbitration claims due to MedCap and Provident sales can now see closure. “We are very pleased to put this matter behind us,” said Janine Wertheim, a spokeswoman for the firm. “To the extent an individual arbitration claim required disclosure on a representative's U4 when the arbitration was filed, the settlement of each arbitration will be treated like any other settlement and will likewise be disclosed as being resolved by the firm for a given amount with no contribution from the representative.” A form U4 is the registration statement used to file information about the broker with the Financial Industry Regulatory Authority Inc. Firms are less likely to recruit a broker if he or she has open or pending arbitration claims, industry observers said. The settlement of an arbitration claim “means the lawsuit can't come back and bite a new recruiting broker-dealer,” said Larry Papike, president of Cross-Search, a recruiting firm. “The status of pending arbitration was a big problem for brokers.” Securities America brokers from 2003 to 2008 sold about $700 million of MedCap notes. Although other broker-dealers sold the notes, Securities America was by far the biggest distributor of the private placements. The Securities and Exchange Commission in 2009 alleged that both Medical Capital and Provident Royalties had committed fraud. Mr. Furgeson also approved more than $18 million in for fees for the class action lawyers, which will be deducted from the $80 million settlement.

Latest News

Names of more B-Ds that sold deals of bankrupt Inspired Healthcare surface
Names of more B-Ds that sold deals of bankrupt Inspired Healthcare surface

Broker-dealers that sold the defunct securities backed by Inspired Healthcare generated more than $100 million in fees and commissions.

MetLife poll finds high-value home sales are becoming tax-planning events
MetLife poll finds high-value home sales are becoming tax-planning events

A new MetLife survey finds real estate professionals are increasingly steering clients toward tax experts as rising property values leave more sellers facing significant capital gains.

Kestra adds Raymond James recruiter to expand advisor hiring push
Kestra adds Raymond James recruiter to expand advisor hiring push

The independent broker-dealer expands its business development bench with a new recruiter and an internal promotion in the West.

Cerity Partners names Will Peng chief innovation officer
Cerity Partners names Will Peng chief innovation officer

The leading ultra-high-net-worth RIA joins other large wealth firms, including Raymond James and LPL, in creating executive roles focused on artificial intelligence strategy

SPONSORED Who builds the income when the pension disappears?

Dan Biagini of American Equity says the steady decline of pensions, longer lifespans and a reset in interest rates are rewriting how advisors build retirement income

SPONSORED Why direct indexing stopped being optional

Direct indexing is on pace to outgrow ETFs and mutual funds. Northern Trust's Ken Lassner explains why the advisors who get it wish they had started sooner.